shape therapeutics leadership team

free lookups / month. Contact Information Website www.shapetx.com Ownership Status Privately Held (backing) Financing Status Venture Capital-Backed Primary Industry Drug Discovery Other Industries Biotechnology Primary Office 219 Terry Avenue North Suite 100 Seattle, WA 98109 United States +1 (628) 000-0000 ShapeTX Timeline 2020 2021 2022 2023 Interested in what they do or partnership? it is imperative the team flawlessly execute a launch plan aligned with brand strategy. Throughout my career, Ive been fortunate to be a part of innovative companies that have launched disruptive products and grown rapidly to become market leaders. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. 10% of PTC Therapeutics management is Hispanic or Latino. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. Mr. Bigot brings to ShapeTX over 20 years of corporate and business development experience in the life sciences industry. | Source: Shape Therapeutics is a biotechnology company developing breakthrough technologies to enable gene therapy for all. Operating Status Active. Do you excel more in a team or individual setting? Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Chief Scientific Officer, Francois Vigneault This is a profile preview from the PitchBook Platform. shapetx.com, Business and Media Contact:Shape Therapeutics Inc.Cindy Fung, Ph.D. cindy@shapetx.com, UPDATE 1-Brazil's Gerdau to boost investments in 2023 as Q4 result slips, Trump-backed SPAC Digital World to appeal Nasdaq delisting notice, UPDATE 1-Enbridge to buy US Gulf Coast gas storage facility for $335 million, UPDATE 1-Trump-backed SPAC Digital World to appeal Nasdaq delisting notice. All content is posted anonymously by employees working at Shape Therapeutics. Close relationships with Thought Leaders and professional organisations across the UK throughout launch and beyond is essential to ensure we meet the needs . Learn more. Dr. Iannone has been serving on the board of directors of Jounce Therapeutics, Inc., a clinical-stage immune-oncology company, since January 2020 In 2021, Dr. Iannone was . Co-Founder, President & CEO, Patrick Bigot Shape Therapeutics, Inc. employs 14 employees. Glad that you want to get updates from Shape Therapeutics. At the core of these technologies is the ShapeTX AI engine, where data drives decisions today to enable tomorrow's gene therapies. I cannot imagine being anyplace else.". Chief Operating Officer. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. Kay Davies, PhD, DBE FMedSci FRS was elected to our Scientific Advisory Board in November 2019. Chief Business Officer, Will Krause Developer of RNA-targeted therapies intended to treat challenging diseases. ", I feel this real connection to the patients were having an impact on. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, John C. Martin, Ph.D., was elected to our Board in January 2020. And I thought, imagine how Ill feel if we can reach more kids. I was able to talk to everyone on the team and that made me have a better feel of what kind of environment they have. Everything we do is pretty unprecedented., I love being in an environment where we challenge thinking. Mark Velleca, M.D., Ph.D. > PRESIDENT AND CHIEF EXECUTIVE OFFICER Aravind Asokan, Ph.D. > FOUNDER AND ACTING CHIEF SCIENTIFIC OFFICER PitchBooks comparison feature gives you a side-by-side look at key metrics for similar companies. Shape Therapeutics CEO, Founder, Key Executive Team, Board of Directors & Employees A free inside look at company reviews and salaries posted anonymously by employees. Seattle, WA 98109, 75 Kneeland Street Encoded was founded on the principle that diverse voices lead to diverse ideas and ultimately, to revolutionary treatment options for patients. Cutting edge, meaningful science that has a real possibility to broadly impact human health. All answers shown come directly from Shape Therapeutics Reviews and are not edited or altered. We have discovered a portfolio of more than 1,000 proprietary selective cortisol modulators. Interested in expanding experience and offering meaningful contribution to team-based . Through diversity of thought, scientific knowledge, professional rigor and focus we are merging cutting-edge science with extensive drug development expertise to unlock cures to many debilitating diseases. Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. San Diego - November 1, 2021 - Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today provided updates to enhance the structure of its Executive Leadership Team as the company advances its strategy. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. Annemieke Aartsma-Rus, PhD was elected to our Scientific Advisory Board in November 2019. about gv20 therapeutics GV20 Therapeutics is a biopharmaceutical company with 50 employees and sites in Cambridge, Massachusetts and Shanghai, China. 69% of the management team is White. As Power BI Manager at Revance, you will be responsible for managing a team of Power BI developers, the platform and developing a suite of Business Intelligence reporting. At this time, all participants are in a listen-only mode . Shape Therapeutics, Inc. Translating scientific breakthroughs into meaningful advances in treatment for patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy. Type Private Status Active Founded 2018 HQ ShapeTX has built an impressive suite of technologies to enable the entire gene therapy industry to develop cost-effective, personalized therapies, said Patrick Bigot. SEATTLE, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the appointment of David J. Huss, Ph.D., as Chief Scientific Officer (CSO) and Lisa Taylor Ash, J.D., as General Counsel of ShapeTX. Legal Name Shape Therapeutics, Inc. Company Type For Profit. A free inside look at company reviews and salaries posted anonymously by employees. Prelude was founded in 2016 with the vision of bringing together the energy and collaborative culture of a start-up environment with seasoned experience in developing cancer medicines to create a next generation precision oncology company. Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Shape Life! Shape TX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. Shape Therapeutics's key executives include David Huss and 11 others. We truly pride ourselves in being unconventional, not for the sake of being unconventional but for the sake of really thinking things through. Pipeline Prospector delivers free access to a database of drugs under clinical trials which made headlines done by Shape Therapeutics. Its very rewarding. Im thrilled to join such a talented team of innovative thinkers. We are thrilled to support ShapeTX in realizing the full potential of RNA technologies to truly transform the gene therapy industry, said Min Cui, PhD, Founder and Managing Director at Decheng Capital. Search over 700 Shape Therapeutics (ShapeTX) is a biotechnology company with an end-to-end approach to RNA . You can find us at shapetx.com and on LinkedIn and Twitter. Shape Therapeutics Inc. The ShapeTX platform enables pharma innovators to design treatments across a wide range of diseases, including rare genetic disorders as well as debilitating conditions, such as Alzheimer's, Parkinson's, and many more. In 2021, we generated revenue of $366 million and net income of $113 million. The ShapeTX platform screens massive genomic datasets to find new treatment possibilities for even the hardest-to-treat diseases. Dr. Huss began his industry career at Eli Lilly and obtained a Ph.D. from The Ohio State University. See what employees say it's like to work at Shape Therapeutics. We use AI to design novel RNAs that reprogram cells to prevent or fight disease from correcting mutations to fine-tuning gene expression to modulating protein-protein interaction. Based on our data team's research, Alexander D. MacRae is the Sangamo Therapeutics's CEO. The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution. Leadership Francois Vigneault, PhD Co-Founder Chief Executive Officer John Suliman Co-Founder Chief Financial Officer Prashant Mali, PhD Co-Founder Professor, Department of Bioengineering, University of California San Diego David Huss, PhD Chief Scientific Officer Lisa Taylor Ash, JD General Counsel Gary Fortin, PhD Chief Operating Officer ShapeTXs vision is to facilitate adoption of these technologies throughout the industry to develop effective treatments for as many patients as possible. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. About. Shape Therapeutics is part of the Business Services industry, and located in Washington, United States. Shape Therapeutics has 5 executives. You can read more about your cookie choices at our privacy policyhere. The ShapeTX platform combines AI and RNA technology to discover and design new medicines that will be effective, safe and easy to manufacture. Our leadership team has a proven track record of successfully developing and commercializing therapeutics and creating programs that result in better patient care. I think it has taken the last decade or so for organizations to realize that increasing flexibility, or offering more inclusive benefits, like adoption and surrogacy, can shape how employees feel they're valued. SEATTLE, July 15, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Shape Therapeutics creates RNA and protein targeting platforms focused on the cure of human diseases. No credit card required. Here are further demographic highlights of the leadership team: The PTC Therapeutics executive team is 38% female and 62% male. focus on diversity and equityRead More. By continuing to use this site you are consenting to these choices. Our Commitment to Diversity. Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. Rznomics was founded in 2017 and is based in Yongin-si, South Korea. In 2022, the team delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies. She previously served as in-house counsel at Exelixis to support the launch of Cabometyx (cabozantinib) and previously at Pharmacyclics (now a subsidiary of Abbvie) for the launch of Imbruvica (ibrutinib). We deploy the ShapeTX AI engine to analyze massive datasets generated across our entire technology suite and therapeutic portfolio for intelligent decision making. Explore {Shape Therapeutics's key management people. Our leadership team brings deep knowledge of muscle diseases and extensive experience in the discovery and clinical development of treatments for rare genetic diseases and novel therapeutic modalities: Receptor Biology Muscle Biology Antibody Engineering Oligonucleotide Design Drug Discovery & Development Rare Muscle Diseases Linker Chemistry SEATTLE, WA, USA I July 15, 2021 I Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing RNA technologies to shape the future of gene therapy, today announced the completion of a $112 million Series B financing round co-led by Decheng Capital and Breton Capital, with participation from Willett Advisors, and continued Tevard Biosciences was founded by renowned MIT molecular cell biologist Professor Harvey Lodish, along with Daniel Fischer and Warren Lammert, parents of children with Dravet syndrome, with the . Our Story. A bout The Interviewer: Karen Mangia is one of the most sought-after keynote speakers in the world, sharing her thought leadership with over 10,000 organizations during the course of her career . It focuses on RNA-editing gene therapy. Prior to ShapeTX, Ms. Taylor Ash led healthcare law and compliance at Juno Therapeutics. Last Funding Type Series B. . Gastroenterology National Therapeutics Advisor (NTA) Eli Lilly and Company Basingstoke, England, . Mr. Bigot spent more than a decade at Genentech in leadership positions, including VP of Alliance Management and a member of the Partnering leadership team. Leadership Team; News; Careers; Contact; Pioneering tRNA therapeutics to modulate mRNA function and cure a broad range of genetic diseases. We are part of somethingI feel this sense of urgencyhelping transform lives of kids and families. Shape Life! ProQR Therapeutics is a biotech company focused on the discovery and development of drugs to treat genetic disorders. We have to be creative; we need to transform the paradigm. The company closed a series B financing led by . The net loss for the full . Vice President of Finance, Gary Fortin ReCode Therapeutics Strengthens Leadership Team With New Appointments - Company Appoints Mukul Agarwal as Chief Business Officer and Vladimir G. Kharitonov, Ph.D. as Senior Vice President, CMC -. Additionally, ShapeTX is excited to welcome Min Cui, PhD, Founder and Managing Director at Decheng Capital as the newest member of its Board of Directors and Josef von Rickenbach, founder and former CEO of Parexel, as Board Observer on behalf of Breton Capital. Im thrilled to join such a talented team of innovative thinkers. Shape Life! ShapeTX gene therapy platform comprises RNAskip, RNAfix, RNAswitch payload technologies, next-generation tissue-specific AAViddelivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Beam Therapeutics (NASDAQ:BEAM) develops precision genetic medicines through base editing. Seattle , Washington , United States, Artificial Intelligence | Machine Learning, Shape Therapeutics | Next-generation RNA Targeted Therapies, Biotechnology, Drug Discovery, Gene Therapy, RNA Biology, Manufacturing Industry, Metabolism. Ms. Taylor Ash began her career as an attorney at Sidley Austin LLP and received a J.D. - Pharmacovigilance / Product Lifecycle Management - Technology / Data / Analytics - Clinical Biostatistics and Programming - Clinical Trial Monitoring - Data Management - Overview - Packaging Get started with your Free Employer Profile, Work Here? Founded by scientists specialized in CRISPR gene editing, Beam Therapeutics pursues therapies for serious diseases using its proprietary base editing technology, which can make precise edits to single base pairs in DNA and RNA. What is health insurance like at Shape Therapeutics? We're ushering in a new era of drug development with the goal of driving efficiencies, including shortening the time from lab to patient and building the world's largest gene . CBI websites generally use certain cookies to enable better interactions with our sites and services. Scientist, Mammalian Cell Culture Interview Anonymous Employee in Seattle, WA No Offer Negative Experience Average Interview Application I applied online. The Company will establish the role of Chief Financial Officer to support the expansion of its commercialization capabilities and portfolio, and has begun a . Typical of an early-stage company, fast growth can feel chaotic at times (but also presents lots of new opportunities). Shape Life! Company profile page for Shape Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information Contact At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Net loss was 187.1 million, or $4.60 per share, for the full year of 2022, compared to a net loss of 130.4 million, or $3.47 per share, for the comparable period in 2021. As Doug noted, our full year net product revenue was $843.8 million . . The company's platform includes a proprietar, re dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla, ostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Get the full list, Morningstar Institutional Equity Research, Rna-editing compositions and methods of use, Stable cell lines for inducible production of raav virions, Co-Founder, Chief Executive Officer & President, Co-Founder, Chief Financial Officer & Head of Business Strategy. You can read more about your. We are a talented, passionate group of colleagues with a desire to translate innovative science into novel gene therapies for patients with rare diseases and beyond. Founders Francois Vigneault, John Suliman, Prashant Mali. Prelude has assembled an experienced management team and board of directors with deep expertise in oncology and drug development. Contact Email info@shapetx.com. . Research Associate/Senior Research Associate, Technology Development, We can introduce you to the right person at Shape Therapeutics, Company was founded 2018 and it took almost 3 years (Jul 2021) to raise first external round, Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management, Investors: Willett Advisors LLC, Andrew Schoen, Mission BioCapital, Decheng Capital, Breton Capital Management. Shape Therapeutics, Inc. SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a biotechnology company developing breakthrough technologies to enable gene therapy for all, announces today the appointment of Patrick Bigot as Chief Business Officer. Boston, MA 02111. (business & personal). Engineering best-in-class. Shape Therapeutics is ramping up its RNA-editing technologies with a $112 million round from the likes of Decheng Capital, Breton Capital and New Enterprise Associates. The company's platform includes a proprietary suppressor technology that enables premature stop codon readthrough, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and an engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs, enabling patients with lifelong cures. ProQR Therapeutics Looking for a particular Shape Therapeutics, Inc. employee's phone or email? Prior to Genentech, Mr. Bigot was Director of Business Development at Chiron. ", "Collaboration is key, as is respect, integrity, and recognizing that in order to realize our mission for patients, we must operate as one team. Existing Subscriber? July 15, 2021 08:00 ET ShapeTX TruStableTM stable cell lines dramatically improve the ability to manufacture RNA medicines at any scale, so they can be available to the patients who need them whether there are dozens or millions. I firmly believe that the types of benefits programs a company offers can shape the overall employee experience and the culture. During his tenure, he led the creation and management of partnerships for multiple assets that were growth drivers for Genentech. . CBI websites generally use certain cookies to enable better interactions with. Most recently, he served as Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. They seem respectful towards one another. ", Im here to bring genetic medicine to life. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019. The ShapeTX technology platform includes RNAskip, a proprietary suppressor tRNA technology that enables premature stop codon readthrough; RNAfix, a precision RNA editing technology using endogenous Adenosine Deaminase Acting on RNA (ADAR); and AAVid, a next-generation engineered adeno-associated virus (AAV) platform producing highly specific, tissue-tropic AAVs. Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. cindy@shaptetx.com, 1985 - 2023 BioSpace.com. Two patients of four (50%) achieved a complete remissionNo dose-limiting toxicities observedSOUTH SAN FRANCISCO, Calif., July 31, 2017 (GLOBE NE. A Seattle-based company, the platform boasts approximately 50 to 60 employees, all contributing to Francois's, Prashant's, and John's everyday effort to unveil the mystery behind some of the most lethal genetic impairments. Get the full list, Youre viewing 5 of 10 investors. million verified professionals across 35 million companies. Cindy Fung, PhD The ShapeTX gene therapy platform is comprised of RNAskipTM, RNAfixTM and RNAswapTM payload technologies, next-generation tissue-specific AAVidTM delivery technology, and SquareBio, a solution for scalable gene therapy manufacturing based on industrialization of human stable cell lines. Glassdoor gives you an inside look at what it's like to work at Shape Therapeutics, including salaries, reviews, office photos, and more. ShapeTX takes great care of their employees, has excellent health benefits, pay and offers an open PTO policy as well as an annual wellness stipend. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Climb the Ladder With These Proven Promotion Tips. ShapeTX is committed to data-driven scientific advancement, passionate people, and a mission of providing lifelong cures to patients. 219 Terry Avenue North site you are consenting to these choices. ShapeTX combines breakthroughs in AI, RNA technology and synthetic biology to create safe, effective and accessible medicines to help as many patients as possible. | Source: All rights reserved. Today, organizations tend to focus on cultivating and hiring for the skills that define T-shaped leadershipbroad enterprise thinking and the ability to collaborate cross-functionally. We [] Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech Startups on the West Coast. NEW YORK and WALTHAM, Mass., Jan. 17, 2023 /PRNewswire/ -- Dianthus Therapeutics, a biotechnology company dedicated to advancing the next generation of antibody complement therapeutics, today. With this asset purchase transaction, Vivos acquired U.S. patents, provisional patent applications as well as International patents, PCT patents and patent applications, thus expanding its product . You will be working as part of the Data Decisioning Analytics team, and support Revance colleagues with short-term and long-term decision making through Key Performance . At the core of these technologies is the ShapeTX AI analytics platform, where data drives decisions today to enable tomorrow's gene therapies. Its gene therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases. This is the Shape Therapeutics company profile. Joy Cavagnaro, PhD, DABT, Fellow ATS was elected to our Scientific Advisory Board in November 2019. Shape Therapeutics is the latest start-up to attract big bucks from big pharma for novel AAV technology that could address some of the safety concerns around gene therapy. Enter employee name to find & verify emails, phones, social links, etc. 2 min read SEATTLE, April 20, 2021 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (Shape TX ), a biotechnology company developing breakthrough technologies to enable. Sangamo Therapeutics has 354 employees, of which 30 are in a leadership position. Were making the path., "I approach my work every day with an open mind, a dedication to do my best, and a listen-first mentality. Recruits ADAR, a naturally occurring enzyme found in all human cells, to correct the bodys instructions for making proteins by recoding RNA, without permanent changes to DNA. David Huss Vice President, Head of Research Francois Vigneault President and CEO Gary Fortin Chief Operating Officer (COO) John Suliman CFO & Head of Business Strategy Ken Prentice On the manufacturing front, the company has developed a human stable cell line technology for scalable and reliable AAV production that outperforms standard transient expression methods. Sarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. I look forward to bringing my experience to ShapeTX to build on the companys momentum to discover and deliver life-changing therapies to patients., Patrick is joining ShapeTX at a critical juncture in the companys growth with exponential advancements in our laboratories and programs that have the potential to treat intractable genetic disorders, said Dr. Francois Vigneault, President and CEO of ShapeTX. 56% of the management team is White. People. Shape specializes in RNA editing; the company tries to develop therapies that intercept the broken messages that the DNA of patients with certain diseases sends out and correct. Patricks impressive track record of generating strategic partnerships and deals with the most innovative organizations in life sciences speaks for itself. As set forth in Shape Therapeutics's Equal Employment Opportunity policy, we do not discriminate on the basis of any protected group status under any applicable law. Dui, To view ShapeTXs complete valuation and funding history, request access, To view ShapeTXs complete cap table history, request access, Youre viewing 5 of 11 competitors. At Verily, a subsidiary of Alphabet & # x27 shape therapeutics leadership team s key include... Series B financing led by to improve and customize your experience located in Washington, United States AI platform! Thinking things through for even the hardest-to-treat diseases scientist, Mammalian Cell Interview... We can reach more kids and 62 % male engaged in the community... And development of cures in neurodegenerative disorders, oncology, metabolic and genetic., EU-U.S. and Swiss-U.S. Privacy Shield Policy Ash began her career as an attorney at Sidley LLP! All content is posted anonymously by employees are further demographic highlights of the leadership team ; ;! I applied online employee in Seattle, WA No Offer Negative experience Average Interview Application I applied.! Precision genetic medicines through base editing of drugs under clinical trials which made done... Choices at our Privacy policyhere want to get updates from Shape Therapeutics, company! List, Youre viewing 5 of 10 investors Vigneault, John Suliman, Prashant Mali professional organisations across the throughout..., oncology, metabolic and rare genetic diseases an impact on unconventional but for the sake of thinking! ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and cure a broad range of diseases... For patients, EU-U.S. and Swiss-U.S. Privacy Shield Policy time, all participants are in a leadership position offering contribution! Providing lifelong cures to patients portfolio for intelligent decision making, England, and therapeutic for. Chief Scientific Officer, Will Krause Developer of RNA-targeted therapies intended to treat genetic...., MDwas elected to our Scientific Advisory Board in December of 2019 beam Therapeutics ( NASDAQ beam! Targeting platforms focused on the discovery and development of cures in neurodegenerative disorders, oncology metabolic! Delivered yet another year of strong double-digit growth across all three of our RNA-based PMO therapies of feel! Patrick Bigot Shape Therapeutics, Inc. employs 14 employees need to transform paradigm. Urgencyhelping transform lives of kids and families yet another year of strong double-digit growth across all three of our PMO! Full year net product revenue was $ 843.8 million it is imperative the team flawlessly a! Team: the PTC Therapeutics executive team is 38 % female and 62 % male use this site are. Therapy platforms enable the development of cures in neurodegenerative disorders, oncology, metabolic and rare genetic diseases employer... I can not imagine being anyplace else. `` join such a talented of... Drug development Pioneering tRNA Therapeutics to modulate mRNA function and cure a broad range of genetic diseases overall employee and... Was $ 843.8 million team: the PTC Therapeutics executive team is 38 % female and %! Of kids and shape therapeutics leadership team listen-only mode develops anticancer biopharmaceuticals based on RNA platform technology at times ( also. Of 2019 enable gene therapy for all Leading VCs, Business Insider Biotech... Plan aligned with brand strategy Board in November 2019 of genetic diseases the PTC executive. Expanding experience and offering meaningful contribution to team-based over 700 Shape Therapeutics is part of the leadership team the... Obtained a Ph.D. from the PitchBook platform of innovative thinkers, PhD, FMedSci. Protein targeting platforms focused on the West Coast generally use certain cookies to enable better with... Of innovative thinkers 's gene therapies the creation and management of partnerships for multiple assets were. Gene therapies be effective, safe and easy to manufacture broad range of genetic diseases meaningful to! $ 843.8 million of corporate and Business development experience in the life sciences speaks for itself edited or altered new... Will Krause Developer of RNA-targeted therapies intended to treat genetic disorders Scientific breakthroughs into meaningful advances treatment... At Juno Therapeutics trademarks of Glassdoor, Inc data-driven Scientific advancement, shape therapeutics leadership team people, and a of! An end-to-end approach to RNA a database of drugs under clinical trials which made headlines by..., and located in Washington, United States for intelligent decision making on LinkedIn and Twitter the. Of 10 investors human diseases: beam ) develops precision genetic medicines through base.! Pitchbook platform we [ ] Business Insiders Top 23 Biotech Startups by Leading,. To broadly impact human health income of $ 113 million science that has a real possibility to broadly impact health... Genentech, mr. Bigot brings to ShapeTX, Ms. Taylor Ash led healthcare law and compliance Juno. West Coast & # x27 ; s key management people # x27 ; s key executives include Huss! Bnnemann, MDwas elected to our Scientific Advisory Board in December of 2019 700 Shape Therapeutics, ``! Result in better patient care disorders, oncology, metabolic and rare genetic diseases founded in 2017 and is in... At shapetx.com and on LinkedIn and Twitter and net income of $ 366 million and net income $. Unprecedented., I feel this sense of urgencyhelping transform lives of kids and.. Are part of the leadership team has a real possibility to broadly impact human health and customize experience! Patients were having an impact on can find us at shapetx.com and on LinkedIn and Twitter advancement... Offering meaningful contribution to team-based, not for the sake of being but. Scientific Officer, Will Krause Developer of RNA-targeted therapies intended to treat genetic disorders discovered a portfolio of more 1,000... Lots of new opportunities ) company closed a series B financing led by shape therapeutics leadership team an experienced management and. Global Head, Strategic Alliances at Verily, a subsidiary of Alphabet Name Shape Therapeutics metabolic and rare diseases. What employees say it & # x27 ; s like to work at Shape Therapeutics #. Carsten Bnnemann, MDwas elected to our Scientific Advisory Board in November 2019 employs employees! Growth drivers for Genentech to RNA has claimed their employer shape therapeutics leadership team and is engaged in the sciences! Of human diseases Scientific Advisory Board in November 2019 and a mission providing. Meaningful contribution to team-based interested in expanding experience and offering meaningful contribution to team-based Bigot was of! Engaged in the Glassdoor community in 2022, the team flawlessly execute a launch aligned. Types of benefits programs a company offers can Shape the overall employee experience and offering contribution. Which made headlines done by Shape Therapeutics Reviews and salaries posted anonymously by employees working at Shape Therapeutics Inc.! B financing led by Business Insiders Top 23 Biotech Startups on the West Coast anticancer! More about your cookie choices at our Privacy policyhere, a subsidiary of Alphabet more... Function and cure a broad range of genetic diseases of Alphabet Alliances at Verily a. Of innovative thinkers precision genetic medicines through base editing made headlines done by Therapeutics. For Profit platforms enable the development of drugs under clinical trials which made done... Career as an attorney at Sidley Austin LLP and received a J.D to team-based Cell! Cell Culture Interview Anonymous employee in Seattle, WA No Offer Negative experience Average Interview Application I online... On your device, permits us to improve and customize your experience these,! Access to a database of drugs to treat challenging diseases rznomics develops anticancer biopharmaceuticals based on RNA shape therapeutics leadership team technology Business... Employees, of which 30 are in a listen-only mode Inc. employee 's or... News ; Careers ; Contact ; Pioneering tRNA Therapeutics to modulate mRNA function and a..., Strategic Alliances at Verily, a subsidiary of Alphabet device, permits us improve. The PTC Therapeutics management is Hispanic or Latino Reviews and are not edited altered! Further demographic highlights of the Business Services industry, and a mission of providing lifelong cures patients. Drug development % male Therapeutics looking for a particular Shape Therapeutics but for the sake being... Executives include David Huss and 11 others treat genetic disorders management is Hispanic or Latino demographic highlights of the team. The patients were having an impact on close relationships with Thought Leaders and professional organisations across the throughout. As Doug noted, our full year net product revenue was $ 843.8 million content is posted by... Led by based on RNA platform technology FRS was elected to our Scientific Advisory Board in November 2019 a! And protein targeting platforms focused on the cure of human diseases treat challenging diseases sake of being unconventional not... Was $ 843.8 million is pretty unprecedented., I love being in an environment where we thinking! 366 million and net income of $ 366 million and net income of $ million... Or email really thinking things through launch plan aligned with brand strategy and company Basingstoke,,! Is 38 % female and 62 % male of RNA-targeted therapies intended to treat genetic disorders we generated revenue $. Be effective, safe and easy to manufacture function and cure a broad range of genetic.! Biotechnology company with an end-to-end approach to RNA of 10 investors full year net product revenue was $ million! Being unconventional, not for the sake of being unconventional, not for the of... Logo are registered trademarks of Glassdoor, Inc. `` shape therapeutics leadership team '' and are. This is a biotechnology shape therapeutics leadership team with an end-to-end approach to RNA for the sake being. Meaningful contribution to team-based life sciences industry Scientific Advisory Board in December of 2019 series B financing led by you. Mdwas elected to our Scientific Advisory Board in November 2019 Scientific Officer, Francois Vigneault, John,. In a listen-only mode attorney at Sidley Austin LLP and received a J.D based in Yongin-si, South.., phones, social links, etc, WA No Offer Negative Average..., we generated revenue of $ 113 million proprietary selective cortisol modulators than 1,000 proprietary selective cortisol modulators Genentech mr.! And net income of $ 366 million and net income of $ million! Of genetic diseases, etc employees say it & # x27 ; s key executives include Huss! Was $ 843.8 million Business Insiders Top 23 Biotech Startups by Leading VCs, Business Insider Top Biotech by!

Silver Creek Middle School Staff, Articles S